Altimmune, Inc. - Common Stock (ALT)
3.6800
-0.0600 (-1.60%)
NASDAQ · Last Trade: Aug 15th, 2:08 AM EDT
Detailed Quote
Previous Close | 3.740 |
---|---|
Open | 3.700 |
Bid | 3.700 |
Ask | 3.720 |
Day's Range | 3.650 - 3.765 |
52 Week Range | 2.900 - 11.16 |
Volume | 2,888,916 |
Market Cap | 313.08M |
PE Ratio (TTM) | -3.119 |
EPS (TTM) | -1.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,047,825 |
Chart
About Altimmune, Inc. - Common Stock (ALT)
Altimmune Inc is a biotechnology company focused on developing novel therapeutics for the treatment of liver diseases, respiratory infections, and immune-mediated disorders. The company's innovative approach includes the development of immunotherapeutics and vaccine candidates that aim to harness the body’s immune system to combat various health conditions. Altimmune employs advanced scientific techniques to create therapies that can improve patient outcomes and address unmet medical needs in the healthcare landscape. Through its research and development efforts, the company seeks to bring forward transformative treatments that enhance quality of life and offer new solutions for patients facing significant health challenges. Read More
News & Press Releases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 14, 2025
NEW YORK - August 14, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.
Via TheNewswire.com · August 14, 2025
Via Benzinga · August 13, 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 13, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 13, 2025
NEW YORK - August 13, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.
Via TheNewswire.com · August 13, 2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · August 12, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 12, 2025
NEW YORK - August 12, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.
Via TheNewswire.com · August 12, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · August 12, 2025
Altimmune Q2 FY2025 earnings call transcript
Via Benzinga · August 12, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · August 11, 2025
NEW YORK - August 11, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.
Via TheNewswire.com · August 11, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 11, 2025
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 9, 2025
NEW YORK - August 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.
Via TheNewswire.com · August 8, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 8, 2025
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025. Altimmune describes itself as a “clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases.”
By The Rosen Law Firm, P.A. · Via Business Wire · August 7, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 7, 2025
NEW YORK - August 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. (NASDAQ: ALT) of a class action securities lawsuit.
Via TheNewswire.com · August 7, 2025
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases.
By Robbins LLP · Via GlobeNewswire · August 6, 2025
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · August 6, 2025